52692-02-1

Basic information

• Product Name: Phosphorodichloridic acid, phenylmethyl ester
• CAS NO: 52692-02-1
• Molecular Formula: C7H7Cl2O2P
• Molecular Weight: 225.011
• Mol File: 52692-02-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Phosphorodichloridic acid, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphorodichloridic acid, phenylmethyl ester(52692-02-1)
• EPA Substance Registry System: Phosphorodichloridic acid, phenylmethyl ester(52692-02-1)

Safety Data

• Hazardous Substances Data: 52692-02-1(Hazardous Substances Data)

Upstream product

• 100-51-6 benzyl alcohol 

Downstream Products

• 538-37-4 dibenzyl phosphochloridate 
• 84681-49-2 benzyl N,N’-bis(2-chloroethyl)phosphorodiamidate 
• 84681-48-1 benzyl N,N'-bis(ethylene)phosphorodiamidate 

Relevant articles and documents

Identification of new metabolites of ifosfamide in rat urine using ion cluster technique

Metabolism of the anticancer drug ifosfamide was investigated in Sprague-Dawley rats. Along with four known metabolites, namely N2-dechloroethylifosfamide, N3-dechloroethylifosfamide, alcoifosfamide and isophosphoramide mustard, four new urinary metabolites were identified utilizing combined techniques of chemical modification/derivatization, capillary gas chromatography/chemical ionization mass spectrometry (ammonia), deuterium-labeling/ion cluster analysis and chemical synthesis. Secondary metabolites of N2-dechloroethyl and N3-dechloroethylifosfamide formed by 4-hydroxylation, i.e. 4-hydroxy-N2-dechloroethylifosfamide and 4-hydroxy-N3-dechloroethylifosfamide, respectively, and their subsequent decomposition product, N-dechloroethylisophosphoramide mustard, were identified. Secondary dealkylation pathways of N2-dechloroethylifosfamide and/or N3-dechloroethylifosfamide were also demonstrated through characterization of N2,3-didechloroethyl ifosfamide. The key active metabolite of ifosfamide, 4-hydroxyifosfamide, was characterized as a cyanohydrin adduct for the first time.

Uridine phosphamide prodrugs, and preparation methods and medical applications thereof

The invention relates to uridine phosphamide prodrugs, and preparation methods and medical applications thereof. The prodrugs are compounds disclosed as General Formula I, or optical isomers or pharmaceutically acceptable salts thereof. The prodrugs also comprise solvates of the compounds disclosed as General Formula I, or optical isomers or pharmaceutically acceptable salts thereof. The prodrugs provided by the invention can be used for treating viral infectious diseases, especially hepatitis C virus infectious diseases.

Synthetic Method for 2,2'-Disubstituted Fluorinated Binaphthyl Derivatives and Application as Chiral Source in Design of Chiral Mono-Phosphoric Acid Catalyst

A practical synthetic method for 2,2'-disubstituted fluorinated binaphthyl derivatives was achieved using magnesium bis(2,2,6,6-tetramethylpiperamide) [Mg(TMP)2], prepared from LiTMP (2 equiv) and MgBr2 (1 equiv), which allows for access to a variety of fluorinated binaphthyl compounds. The utility of the fluorinated binaphthyl backbone was evaluated in F10BINOL derived chiral mono-phosphoric acid (R)-19 as the chiral Br?nsted acid catalyst. The catalyst (R)-19 performs exceptionally well in the catalytic enantioselective imino-ene reaction, demonstrating the potential of a fluorinated binaphthyl framework. Chirality 27:464-475, 2015.